Chorionic Gonadotropin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The chorionic gonadotropin market size has grown strongly in recent years. It will grow from $1.34 million in 2025 to $1.43 million in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to growth of infertility treatments, established role in ovulation induction, increasing male reproductive disorders, hospital based fertility programs, long standing clinical usage.

The chorionic gonadotropin market size is expected to see strong growth in the next few years. It will grow to $1.82 million in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising infertility rates globally, expansion of assisted reproductive technologies, growing awareness of male hormonal disorders, increased oncology diagnostic applications, wider availability through retail pharmacies. Major trends in the forecast period include rising use in assisted reproductive treatments, growing application in male hypogonadism therapy, increased demand for fertility hormone therapies, expansion of diagnostic use as tumor marker, improved formulations and dosage accuracy.

The increasing prevalence of infertility issues is expected to drive the growth of the chorionic gonadotropin market in the coming years. Infertility is defined as the inability to conceive after one year of regular, unprotected sexual intercourse for couples under the age of 35, or after six months for couples aged 35 and above. The rising incidence of infertility is largely attributed to delayed childbearing, as many individuals choose to have children later in life, as well as lifestyle factors such as obesity and smoking, which adversely affect reproductive health. Chorionic gonadotropin (hCG) is used in fertility treatments to induce ovulation in women, support the luteal phase to maintain pregnancy, and stimulate testosterone production in men to improve sperm count, thereby addressing a range of infertility concerns. For instance, in April 2023, according to the World Health Organization (WHO), a Switzerland-based specialized agency, around 17.5% of the adult population, or 1 in 6 people globally, experience infertility, highlighting the urgent need to enhance access to affordable and high-quality fertility care. Therefore, the growing prevalence of infertility issues is contributing to the expansion of the chorionic gonadotropin market.

The growth in assisted reproductive technologies is also expected to propel the chorionic gonadotropin market going forward. Assisted reproductive technologies (ART) encompass medical procedures that assist individuals or couples in achieving pregnancy when natural conception is not possible. The increase in ART usage is driven by higher infertility rates, advancements in medical technology, delayed childbearing, and improved accessibility to treatment options. Chorionic gonadotropin (hCG) plays a critical role in ART by triggering ovulation and supporting the luteal phase following embryo transfer to promote successful fertilization and early pregnancy. For example, in May 2024, according to Cofertility, a US-based healthcare company, demand for egg freezing increased significantly, with cycle numbers rising by nearly 40% between 2022 and 2023. Therefore, the rise in assisted reproductive technologies is fueling the growth of the chorionic gonadotropin market.

Major companies operating in the chorionic gonadotropin market are concentrating on developing innovative solutions, such as saliva-based pregnancy tests, to enhance convenience, accuracy, and accessibility. A saliva-based pregnancy test is a non-invasive diagnostic approach that detects pregnancy by analyzing saliva samples for the presence of human chorionic gonadotropin (hCG), a hormone produced during pregnancy. For instance, in June 2023, Salignostics, an Israel-based biotechnology company, launched the world’s first saliva-based pregnancy test. This innovative product enables women to determine pregnancy using a saliva sample instead of urine, detecting hCG with results available within 5 to 15 minutes. Salistick provides a more comfortable and convenient testing experience, allowing users to test anywhere and easily share the moment with partners or loved ones.

Major companies operating in the chorionic gonadotropin market are Ferring Pharmaceuticals.

North America was the largest region in the chorionic gonadotropin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chorionic gonadotropin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chorionic gonadotropin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the chorionic gonadotropin market by increasing costs related to imported active pharmaceutical ingredients, hormone purification equipment, and sterile packaging materials. These impacts are more pronounced in human chorionic gonadotropin products used in fertility clinics and hospitals. Regions dependent on cross-border pharmaceutical trade such as north america and europe face pricing and supply pressure. However, tariffs are encouraging local hormone manufacturing and regional sourcing strategies. This is strengthening supply reliability and reducing long-term import dependency.

The chorionic gonadotropin market research report is one of a series of new reports that provides chorionic gonadotropin market statistics, including chorionic gonadotropin industry global market size, regional shares, competitors with a chorionic gonadotropin market share, detailed chorionic gonadotropin market segments, market trends and opportunities, and any further data you may need to thrive in the chorionic gonadotropin industry. This chorionic gonadotropin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chorionic gonadotropin, specifically human chorionic gonadotropin (hCG), is a hormone produced by the placenta during pregnancy that supports the corpus luteum to maintain progesterone levels. It is used in medical treatments to induce ovulation in women, treat hypogonadism in men, and as a tumor marker for certain cancers.

The main types of chorionic gonadotropin are human chorionic gonadotropin and animal chorionic gonadotropin. Human chorionic gonadotropin (hCG) is a hormone primarily produced during pregnancy by cells that form the placenta, which nourishes the fertilized egg after it has attached to the uterine wall. It was distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, for various therapeutic applications, such as male hypogonadism, female infertility treatment, oligospermic treatment, cryptorchidism treatment, chronic pain, and others. It includes end users such as research institutions and pharmaceutical companies.

The chorionic gonadotropin market consists of sales of products including follicle-stimulating hormone, luteinizing hormone, menotropins, gonadotropin-releasing hormone, and clomiphene citrate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.